NCT04453982

Brief Summary

The Canadian Paediatric Society recommends breastfeeding during COVID-19 infection. Human milk is the best form of infant nutrition providing significant protection against many illnesses for term and preterm infants. When mothers of hospitalized infants are unable to supply their milk, the recommended supplement is human donor milk. The impact of a pandemic on human milk banking is unknown. This study seeks to address this public health issue. Donor milk will be collected from the Rogers Hixon Ontario Human Milk Bank at Sinai Health System in Toronto. Samples will be analyzed for the COVID-19 virus specific nucleic acid and antibody in real-time and results will be immediately disseminated to relevant organizations to inform local, national and international guidelines surrounding donor milk banking to protect the health of infants.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
384

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jun 2020

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 21, 2020

Completed
8 days until next milestone

First Submitted

Initial submission to the registry

June 29, 2020

Completed
2 days until next milestone

First Posted

Study publicly available on registry

July 1, 2020

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 27, 2023

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 27, 2023

Completed
Last Updated

June 6, 2025

Status Verified

June 1, 2025

Enrollment Period

2.8 years

First QC Date

June 29, 2020

Last Update Submit

June 3, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Prevalence of SARS-CoV-2 in breastmilk

    To describe the prevalence of human milk donations received at the Ontario Human Milk Bank that test positive for SARS-CoV-2

    2 months

  • Prevalence of SARS-CoV-2 antibody in breastmilk

    To describe the prevalence of human milk donations received at the Ontario Human Milk Bank with antibodies for SARS-CoV-2

    2 months

Study Arms (1)

Human milk donors

Other: Human milk donors

Interventions

Human milk donors for the Rogers Hixon Ontario Human Milk Bank

Human milk donors

Eligibility Criteria

Sexall
Healthy VolunteersYes
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Community sample

You may qualify if:

  • \- Human milk donor for the Rogers Hixon Ontario Human Milk Bank

You may not qualify if:

  • \- None

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Sinai Health System

Toronto, Ontario, M5G 1X5, Canada

Location

Related Publications (1)

  • Ismail S, Unger S, Budylowski P, Poutanen S, Yau Y, Jenkins C, Anwer S, Christie-Holmes N, Kiss A, Mazzulli T, Johnstone J, McGeer A, Whittle W, Parvez B, Gray-Owen SD, Stone D, O'Connor DL. SARS-CoV-2 antibodies and their neutralizing capacity against live virus in human milk after COVID-19 infection and vaccination: prospective cohort studies. Am J Clin Nutr. 2024 Feb;119(2):485-495. doi: 10.1016/j.ajcnut.2023.10.008. Epub 2023 Dec 14.

    PMID: 38309831BACKGROUND

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR INVESTIGATOR
PI Title
Scientist

Study Record Dates

First Submitted

June 29, 2020

First Posted

July 1, 2020

Study Start

June 21, 2020

Primary Completion

April 27, 2023

Study Completion

April 27, 2023

Last Updated

June 6, 2025

Record last verified: 2025-06

Locations